Merck & Co, Accenture and UPS are all set to exit application integration and data management platform developer Liaison Technologies through the acquisition.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

A round up of all the latest news on www.globalcorporateventuring.com for our subscribers

Illumina, WuXi PharmaTech, Kangmei and Institut Mérieux-backed synthetic DNA producer Twist Bioscience floated at the bottom of its range.

UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.

Stanford-StartX Fund has exited business intelligence software provider DataFox in an acquisition of undisclosed size by Oracle.

The Legend Capital-backed sacral neuromodulation device developer floated in the middle of its range while upping the number of shares in the IPO.

Novartis and Access Industries were among the investors that bought $37.5m of the shares, which the cell therapy developer issued at a downgraded price.

Fashion e-commerce marketplace Spring had raised more than $97m from investors including GV, and has been bought for an undisclosed sum.